Ignite Creation Date:
2024-05-05 @ 10:22 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001354
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
1999-11-03
Brief Title:
Interleukin-2 Therapy for HIV Infection - Supplemental Procedures
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
A Randomized Trial of Interleukin-2 Therapy in HIV-Infected Patients
Status:
COMPLETED
Status Verified Date:
2002-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Certain patients who are participating in NIH protocols involving interleukin-2 IL-2 therapy for HIV disease may be requested to have the following changes or additions to their study protocol
3-day subcutaneous sc IL-2 administration Patients currently receiving IL-2 intravenously injections through a vein may switch to subcutaneous administration injections under the skin Injections are given twice a day for 3 to 5 days one treatment cycle with cycles repeated no more often than every 8 weeks
Home treatment of sc IL-2 Home administration of IL-2 injections involves less frequent data and safety monitoring and no medical evaluations at the Clinical Center except at the beginning of each cycle Participants will receive IL-2 cycles on the same schedule they followed in their original protocol They will be seen at the Clinical Center at regularly scheduled follow-up visits between cycles and for a medical evaluation and blood drawing before the start of each cycle to determine the safety of administering the next cycle During the home cycle the patients case manager or other team member will place monitoring telephone calls on days 2 and 4 of the cycle and again a week later The timing and number of these calls may change depending on the findings of ongoing assessments of their usefulness Patients will be required to notify the study team promptly of complications or other problems that develop with therapy
Stored specimens and HLA testing Stored blood and tissue samples from patients will be used for future research on HIV AIDS and related medical conditions and the immune system The samples may be labeled with no identifying information with identifying information such as the patients name or with a code that only the study team can link to the patient Some of the blood drawn may be used for HLA typing a genetic test of markers of the immune system Usually used to match bone marrow or organ transplants HLA type might also be used to try to identify factors associated with the progression of HIV disease or related conditions Determining HLA type is also necessary to be able to perform certain research studies
Tonsillar biopsy Examination of tonsil tissue may provide information on the effects of IL-2 on the immune system and the expression of HIV Patients in the randomized IL-2 study 93-CC-0113 may have tonsillar biopsies done up to three times-soon after enrollment after month 4 and after month 12 Patients in the open IL-2 study 91-CC-0143 would have procedures no more often than every 3 months with the following exception patients in either study who are willing to have repeat biopsies performed during IL-2 therapy will have the procedure done up to three times during a round of IL-2 before Il-2 therapy day 2-3 or IL-2 therapy and day 4-6 of IL-2 therapy if the sequential biopsies can be safely performed The area to be biopsied will be numbed with a local anesthetic and 1 to 2 small pieces of tissue will be biopsied
Skin biopsy Examination of skin tissue may help to explain how IL-2 causes changes in the skin Biopsies will be obtained from areas of the skin that have been affected by IL-2 as well as from normal unaffected areas for comparison Patients with Kaposi sarcoma will also have biopsies of normal skin to allow comparison with IL-2-induced changes in the Kaposi sarcoma lesions The areas to be biopsied will be numbed with local anesthetic and a 2-mm 110th-inch piece of skin will be biopsied from each site
3-day subcutaneous sc IL-2 administration Patients currently receiving IL-2 intravenously injections through a vein may switch to subcutaneous administration injections under the skin Injections are given twice a day for 3 to 5 days one treatment cycle with cycles repeated no more often than every 8 weeks
Home treatment of sc IL-2 Home administration of IL-2 injections involves less frequent data and safety monitoring and no medical evaluations at the Clinical Center except at the beginning of each cycle Participants will receive IL-2 cycles on the same schedule they followed in their original protocol They will be seen at the Clinical Center at regularly scheduled follow-up visits between cycles and for a medical evaluation and blood drawing before the start of each cycle to determine the safety of administering the next cycle During the home cycle the patients case manager or other team member will place monitoring telephone calls on days 2 and 4 of the cycle and again a week later The timing and number of these calls may change depending on the findings of ongoing assessments of their usefulness Patients will be required to notify the study team promptly of complications or other problems that develop with therapy
Stored specimens and HLA testing Stored blood and tissue samples from patients will be used for future research on HIV AIDS and related medical conditions and the immune system The samples may be labeled with no identifying information with identifying information such as the patients name or with a code that only the study team can link to the patient Some of the blood drawn may be used for HLA typing a genetic test of markers of the immune system Usually used to match bone marrow or organ transplants HLA type might also be used to try to identify factors associated with the progression of HIV disease or related conditions Determining HLA type is also necessary to be able to perform certain research studies
Tonsillar biopsy Examination of tonsil tissue may provide information on the effects of IL-2 on the immune system and the expression of HIV Patients in the randomized IL-2 study 93-CC-0113 may have tonsillar biopsies done up to three times-soon after enrollment after month 4 and after month 12 Patients in the open IL-2 study 91-CC-0143 would have procedures no more often than every 3 months with the following exception patients in either study who are willing to have repeat biopsies performed during IL-2 therapy will have the procedure done up to three times during a round of IL-2 before Il-2 therapy day 2-3 or IL-2 therapy and day 4-6 of IL-2 therapy if the sequential biopsies can be safely performed The area to be biopsied will be numbed with a local anesthetic and 1 to 2 small pieces of tissue will be biopsied
Skin biopsy Examination of skin tissue may help to explain how IL-2 causes changes in the skin Biopsies will be obtained from areas of the skin that have been affected by IL-2 as well as from normal unaffected areas for comparison Patients with Kaposi sarcoma will also have biopsies of normal skin to allow comparison with IL-2-induced changes in the Kaposi sarcoma lesions The areas to be biopsied will be numbed with local anesthetic and a 2-mm 110th-inch piece of skin will be biopsied from each site
Detailed Description:
This study is designed as a randomized open label trial to evaluate the effect of interleukin-2 IL-2 on CD4 counts in patients with HIV infection and CD4 counts above 200 cellsmm3 60 patients will receive either antiretroviral therapy or antiretroviral therapy plus IL-2 administered by continuous infusion at a dose of 18 million international units IUday for 5 days every two months for 1 year Patients will be seen at the NIH every 4 weeks at which time immune parameters including CD4 number and percent will be determined
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 93-I-0113 | None | None | None |